<DOC>
	<DOCNO>NCT02408549</DOCNO>
	<brief_summary>Assessment long-term safety efficacy oral lacosamide ( LCM ) adjunctive therapy uncontrolled primary generalize tonic-clonic ( PGTC ) seizures subject &gt; = 4 year age idiopathic generalize epilepsy ( IGE ) . This study enroll subject LCM SP0982 ( NCT02408523 ) study .</brief_summary>
	<brief_title>Safety Efficacy Lacosamide Additional Therapy Patients Suffering From Epileptic Tonic Clonic Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy , Generalized</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject must complete eligible Baseline failure parent study ( SP0982 ) . Note : Other subject screen SP0982 may consider rollover EP0012 investigator considers subject could benefit treatment openlabel lacosamide ( LCM ) base prior discussion approval UCB Study Physician representative . Subject receive investigational drug use experimental device addition Lacosamide ( LCM ) Subject meet withdrawal criterion SP0982 experience ongoing serious adverse event ( SAE ) Subject active suicidal ideation indicate positive response ( `` Yes '' ) either Question 4 Question 5 `` Since Last Visit '' version ColumbiaSuicide Severity Rating Scale ( CSSRS ) Subject &gt; =2x upper limit normal ( ULN ) following : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , &gt; ULN total bilirubin ( â‰¥1.5xULN total bilirubin know Gilbert 's syndrome ) . If subject elevation total bilirubin &gt; ULN &lt; 1.5xULN , fractionate bilirubin identify possible undiagnosed Gilbert 's syndrome ( ie , direct bilirubin &lt; 35 % ) . For randomized subject Baseline result &gt; ULN ALT , AST , ALP , total bilirubin , Baseline diagnosis and/or cause clinically meaningful elevation must understand recorded Case Report form ( CRF ) . If subject &gt; ULN ALT , AST , ALP meet exclusion limit screening , repeat test , possible , prior dosing ensure ongoing clinically relevant increase . In case clinically relevant increase , inclusion subject must discuss Medical Monitor . Tests result ALT , AST , ALP 25 % exclusion limit may repeat confirmation . This include rescreening .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Children</keyword>
	<keyword>Primary Generalized Tonic Clonic seizure</keyword>
	<keyword>Idiopathic Generalized Epilepsy</keyword>
	<keyword>Adults</keyword>
</DOC>